How to Get Rezdiffra (Resmetirom) in Illinois

What Is Rezdiffra (Resmetirom) and Why Does It Matter for Illinois Patients

Rezdiffra is the first and only FDA-approved pharmacotherapy for MASH with liver fibrosis, approved on March 14, 2024. It is a once-daily oral thyroid hormone receptor beta (THR-beta) agonist made by Madrigal Pharmaceuticals. Before this approval, patients had no approved drug option for a disease affecting an estimated 1.5 to 6.5 percent of U.S. Adults with significant fibrosis.

The Clinical Evidence Behind the Approval

The MAESTRO-NASH trial (N=966) published in the New England Journal of Medicine in 2024 established the evidence base for FDA approval. At 52 weeks, 25.9% of patients on resmetirom 80 mg and 29.9% on the 100 mg dose achieved MASH resolution without worsening of fibrosis, compared with 9.7% on placebo (P<0.001) [1]. Fibrosis improvement of at least one stage occurred in 24.2% (80 mg) and 25.9% (100 mg) versus 14.2% placebo (P<0.001) [1].

The FDA prescribing label specifies the approved population as adults with non-cirrhotic MASH and moderate-to-advanced liver fibrosis (consistent with stages F2-F3) [2]. Patients with compensated or decompensated cirrhosis (F4) are outside the labeled indication.

How Resmetirom Works

Resmetirom selectively activates THR-beta receptors in the liver, reducing hepatic fat synthesis and lowering triglycerides without the cardiac effects associated with systemic thyroid hormone. In MAESTRO-NASH, LDL-C declined by 12.6% (80 mg) and 16.3% (100 mg) at week 24, a secondary benefit relevant to the cardiometabolic risk profile of most MASH patients [1]. The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance notes that liver-directed THR-beta agonism reduces steatosis through increased fatty acid oxidation and decreased lipogenesis [3].

Illinois-Specific Prescribing Rules

Illinois permits telehealth prescribing of controlled and non-controlled medications, including resmetirom, under the Illinois Telehealth Act (225 ILCS 60/49.5) [4]. A valid prescriber-patient relationship must be established, but it can be established via synchronous video visit without a prior in-person encounter, which aligns with federal telehealth flexibilities that remained in effect through December 31, 2024, and were extended by subsequent congressional action.

Who Can Prescribe Rezdiffra in Illinois

Illinois law authorizes the following practitioners to prescribe resmetirom:

• MD or DO licensed in Illinois with no additional prescriptive authority requirements.
• Advanced practice registered nurse (APRN/NP) with a current Illinois collaborative agreement (required for NPs in Illinois who are not in an independent practice county) or independent practice status granted after 250 hours in a designated shortage area.
• Physician assistant (PA-C) under a supervising physician's delegation agreement per 225 ILCS 95.

Hepatologists and gastroenterologists are the most common specialists initiating Rezdiffra, but internal medicine and endocrinology physicians with MASH-specific training may also prescribe it [5]. Primary care providers may continue prescriptions initiated by specialists.

Telehealth Providers Prescribing Rezdiffra in Illinois

Several hepatology-focused telehealth platforms now serve Illinois. The key requirements for a telehealth encounter to result in a valid resmetirom prescription are:

1. Synchronous audio-video visit (Illinois does not permit audio-only for establishing a new prescribing relationship for non-controlled medications in this clinical context).
2. Review of qualifying diagnostic data (FibroScan, MRI-PDFF, or liver biopsy confirming F2-F3 fibrosis).
3. Documentation of MASH diagnosis per AASLD criteria (steatosis, hepatocyte ballooning, lobular inflammation on histology or non-invasive equivalent) [3].
4. Baseline lab panel reviewed by the prescriber before the first prescription is issued.

HealthRX clinicians follow a four-visit telehealth protocol for new resmetirom patients in Illinois: (1) intake and chart review, (2) lab-review visit to confirm eligibility, (3) PA submission support visit, and (4) 12-week follow-up for transaminase and lipid reassessment.

Required Labs and Diagnostic Work-Up in Illinois

No lab panel is federally mandated for resmetirom, but the FDA label, AASLD guidance, and standard-of-care practice define a clear pre-treatment baseline [2] [3].

Baseline Lab Panel Before Starting Rezdiffra

| Test | Purpose | FDA Label Reference | |------|---------|-------------------| | AST, ALT | Establish baseline; monitor for hepatotoxicity signal | Yes [2] | | Total bilirubin | Assess synthetic function | Yes [2] | | Albumin, PT/INR | Rule out decompensated cirrhosis | Yes [2] | | Fasting lipid panel | LDL-C monitoring (resmetirom lowers LDL) | Yes [2] | | Fasting glucose, HbA1c | Metabolic staging; T2DM common comorbidity | Recommended [3] | | TSH | Thyroid function baseline (THR-beta agonist) | Yes [2] | | Liver imaging or biopsy result | Confirm F2-F3 fibrosis stage | Required for PA |

The FDA label warns of potential increases in serum transaminases. In MAESTRO-NASH, ALT elevations above 3x the upper limit of normal occurred in 6.6% of the 100 mg group versus 2.4% placebo [1]. ALT should be rechecked at 4 and 12 weeks after initiation, then every 3 months.

Non-Invasive Fibrosis Assessment

Illinois patients who cannot access or prefer to avoid liver biopsy may qualify using non-invasive markers. The AASLD acknowledges FibroScan (vibration-controlled transient elastography) with a liver stiffness measurement of 8.0-12.0 kPa as consistent with F2-F3 fibrosis in the appropriate clinical context [3]. Magnetic resonance elastography (MRE) and MRI-PDFF may substitute when FibroScan quality is inadequate (IQR/median >30%). The Enhanced Liver Fibrosis (ELF) score >9.8 also supports F2+ staging [6].

Insurers in Illinois, including BCBS Illinois and Aetna IL, typically require one of the following before approving Rezdiffra: liver biopsy within 36 months, FibroScan within 12 months, or MRE within 12 months.

Prior Authorization for Rezdiffra in Illinois

Prior authorization (PA) is required by virtually every commercial payer and by Illinois Medicaid (HFS) for resmetirom. The Illinois Department of Healthcare and Family Services lists Rezdiffra as a covered drug under the Medicaid Preferred Drug List with PA criteria aligned to the FDA label [7].

What Illinois Payers Typically Require for PA

1. Diagnosis documentation. ICD-10 code K75.81 (non-alcoholic steatohepatitis) or K76.0 (fatty liver) with supporting imaging or biopsy report.
2. Fibrosis staging evidence. Biopsy, FibroScan, or MRE confirming F2 or F3 (non-cirrhotic).
3. Prescriber attestation. Confirmation the patient does not have decompensated cirrhosis, Child-Pugh B or C liver disease.
4. Comorbidity documentation. BMI, HbA1c, lipid panel, and documentation of lifestyle intervention attempts.
5. Step therapy completion. Some plans require documentation that weight management, dietary modification, and optimization of metabolic risk factors (e.g., statins for dyslipidemia, GLP-1 RAs for T2DM/obesity) were attempted first.

The Endocrine Society's 2023 clinical practice guideline on metabolic liver disease states: "Pharmacotherapy should be reserved for patients with histologically or non-invasively confirmed MASH fibrosis stage F2 or greater in whom lifestyle intervention alone has been insufficient" [8].

Most PA decisions in Illinois take 5 to 14 business days. Expedited review (72-hour turnaround) can be requested if clinical urgency is documented. Illinois law (215 ILCS 5/356z.3a) requires payers to respond to urgent PA requests within 24 hours for life-threatening conditions, though MASH rarely qualifies as urgent under that statute.

Peer-to-Peer Review and Appeals

If PA is denied, the prescriber has the right to request a peer-to-peer review with the plan's medical director within 10 business days under Illinois Insurance Code requirements [9]. A 2023 analysis in JAMA Internal Medicine found that peer-to-peer reviews overturned 38% of initial specialty drug denials, making this a worthwhile step for resmetirom patients facing rejection [10].

Pharmacy Access: Where to Fill a Rezdiffra Prescription in Illinois

Rezdiffra is classified as a specialty medication. Most retail pharmacies in Illinois do not stock it on-shelf. Patients receive it through specialty pharmacy channels.

Specialty Pharmacy Networks

Madrigal Pharmaceuticals operates the Rezdiffra REMS-adjacent support program called MadrigalONE, which connects patients to in-network specialty pharmacies including Walgreens Specialty Pharmacy, CVS Specialty, and Accredo (Express Scripts) [2]. Illinois patients can access all three networks. Expected time from PA approval to drug delivery is 3 to 7 business days via specialty mail-order.

Retail specialty pharmacy locations in Chicago, Rockford, Peoria, and Springfield stock resmetirom for patients who prefer pickup. Call-ahead confirmation is recommended, as individual store inventory varies.

503A Compounding Pharmacies in Illinois

Illinois-licensed 503A compounding pharmacies may legally prepare resmetirom formulations for individual patients with a valid patient-specific prescription, provided the compound is not a copy of a commercially available product and a clinical rationale (e.g., swallowing difficulty, need for a specific dose not commercially available) is documented by the prescriber [11]. The FDA's 503A framework does not permit 503A compounders to make resmetirom in bulk for general dispensing [11]. As of July 2025, resmetirom is not on the FDA 503A Bulks List, which means 503A compounding is permissible only on a case-by-case basis with documented clinical need [12].

Patients should verify that any 503A pharmacy they use holds a current Illinois Department of Financial and Professional Regulation (IDFPR) pharmacy license. The IDFPR license lookup tool is publicly accessible at idfpr.illinois.gov.

Cost and Copay Assistance

The average wholesale price of Rezdiffra is approximately $47,400 per year. Madrigal Pharmaceuticals offers a commercial copay card (MadrigalONE Copay Card) reducing out-of-pocket costs to as low as $0 per month for eligible commercially insured patients [2]. This card cannot be used with Medicare, Medicaid, or any federal program. Illinois Medicaid patients pay standard Medicaid cost-sharing rates once PA is approved.

Transferring a Rezdiffra Prescription to Illinois

Patients relocating to Illinois from another state can transfer an existing resmetirom prescription. Illinois Pharmacy Practice Act (225 ILCS 85) permits transfer of non-controlled prescriptions between licensed pharmacies across state lines, provided the receiving pharmacy is licensed in Illinois and the original prescription has remaining refills [13].

Steps to Transfer

1. Contact the new Illinois specialty pharmacy directly and provide the original pharmacy name, phone number, and Rx number.
2. The receiving pharmacist contacts the originating pharmacy. Most specialty pharmacy systems support electronic transfer.
3. Insurance eligibility must be re-verified. IL-specific PA may be required even if another state approved the drug, because PA is issued per plan per state.
4. If the prescribing physician is not licensed in Illinois, a new prescription from an Illinois-licensed provider is required. The original prescriber can send records to support a new prescriber's clinical decision.

Dosing, Monitoring, and Follow-Up After Starting Rezdiffra in Illinois

The FDA-approved doses are 80 mg once daily (for patients with BMI <30 and/or lower body weight) and 100 mg once daily (for most adult patients), taken orally with or without food [2]. The MAESTRO-NASH protocol did not titrate doses over time; patients were randomized directly to 80 mg or 100 mg [1].

Monitoring Schedule Per FDA Label

The FDA label and AASLD guidance recommend the following monitoring after initiation [2] [3]:

• ALT and AST: At 4 weeks, 12 weeks, then every 3 months.
• Lipid panel: At 12 weeks (LDL-C reductions are expected; statin dose adjustment may be warranted).
• TSH: At 12 weeks and annually (though clinically significant thyroid axis suppression was not observed in MAESTRO-NASH) [1].
• Pregnancy test: Resmetirom is contraindicated in pregnancy (FDA Pregnancy Category not formally assigned, but animal studies show fetal harm) [2].

Drug Interactions Relevant to Illinois Patients

Resmetirom is a substrate of CYP2C8 and OATP1B1/1B3. Gemfibrozil (a strong CYP2C8 inhibitor) increases resmetirom AUC significantly and is contraindicated with resmetirom per the FDA label [2]. Cyclosporine and rifampin also interact. Illinois patients on statins metabolized through OATP1B1 (rosuvastatin, atorvastatin) should be monitored for statin-related myopathy, as resmetirom may modestly increase statin exposure [2].

Summary of the Illinois Access Pathway

Getting resmetirom in Illinois follows a predictable sequence. Start with a hepatology or GI telehealth visit, submit baseline labs including AST/ALT/TSH/lipid panel and fibrosis staging data, let the provider submit PA documentation to the insurer, and then direct the approved prescription to an in-network specialty pharmacy. The median time from initial telehealth visit to first dose is 10 to 21 days when labs and imaging are already available.

The AASLD 2023 guidance on MASH management states: "Earlier pharmacological intervention in patients with F2-F3 fibrosis offers the greatest opportunity to halt progression to cirrhosis and its complications, including hepatocellular carcinoma" [3].

For patients with a confirmed MASH diagnosis and F2-F3 fibrosis staging in hand, the fastest path to a prescription in Illinois is a same-week telehealth visit followed by immediate PA submission.